Monoclonal Gammopathy of Undetermined Significance Clinical Trials

12 recruiting

Monoclonal Gammopathy of Undetermined Significance Trials at a Glance

19 actively recruiting trials for monoclonal gammopathy of undetermined significance are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Commack, Harrison, and Boston. Lead sponsors running monoclonal gammopathy of undetermined significance studies include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and University of Miami.

Browse monoclonal gammopathy of undetermined significance trials by phase

Treatments under study

About Monoclonal Gammopathy of Undetermined Significance Clinical Trials

Looking for clinical trials for Monoclonal Gammopathy of Undetermined Significance? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Monoclonal Gammopathy of Undetermined Significance trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Monoclonal Gammopathy of Undetermined Significance clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Not Applicable

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami120 enrolled1 locationNCT07446777
Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS60 enrolled4 locationsNCT07214324
Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center200 enrolled1 locationNCT02726750
Recruiting
Phase 2

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07209371
Recruiting
Not Applicable

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center180 enrolled8 locationsNCT05640843
Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaAL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia760 enrolled4 locationsNCT06383143
Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center400 enrolled1 locationNCT05136807
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami1,000 enrolled1 locationNCT05361694
Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceAL Amyloidosis+1 more
Ohio State University Comprehensive Cancer Center5,000 enrolled1 locationNCT01408225
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting
Not Applicable

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceMultiple Myeloma, Smoldering
Memorial Sloan Kettering Cancer Center200 enrolled7 locationsNCT06055894
Recruiting

Sleep Apnea in Patients With MGUS and MM

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance
Michael Tomasson200 enrolled1 locationNCT04114084
Recruiting

Whole Body MRI in Oncology

Advanced Breast CancerAdvanced Prostate CancerMultiple Myeloma+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1,000 enrolled3 locationsNCT06895291
Recruiting

Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance (MGUS)M-Protein+1 more
Zhujiang Hospital2,990 enrolled1 locationNCT06690593
Recruiting
Phase 2

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Prostate CancerMultiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
University of Rochester40 enrolled1 locationNCT04731844
Recruiting

The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study

Multiple MyelomaMonoclonal Gammopathy of Undetermined Significance
Shanghai Zhongshan Hospital10,000 enrolled1 locationNCT05965115
Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+9 more
Peking University First Hospital2,000 enrolled1 locationNCT05283993